DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients

By Rieck Mariana   Schumacher-Schuh Artur F   Altmann Vivian   Francisconi Carolina LM   Fagundes Paulo TB   Monte Thaís L   Callegari-Jacques Sidia M   Rieder Carlos RM   Hutz Mara H  

Pharmacogenomics, Vol. 13, Iss. 15, 2012-11 ,pp. : 1701-1710

Future Medicine

Access to resources Recommend Favorite

Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System

By  

Current Medicinal Chemistry, Vol. 23, Iss. 9, 2016-03 ,pp. : 874-883

Bentham Science Publishers

Access to resources Recommend Favorite

Levodopa-Induced Response Fluctuations in Patients with Parkinson’s Disease: Strategies for Management

By van Laar T.  

CNS Drugs, Vol. 17, Iss. 7, 2003-01 ,pp. : 475-489

Adis International

Access to resources Recommend Favorite

Treating and Preventing Levodopa-Induced Dyskinesias: Current and Future Strategies

By Durif F.  

Drugs & Aging, Vol. 14, Iss. 5, 1999-05 ,pp. : 337-345

Adis International

Access to resources Recommend Favorite

Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease

By Müller Thomas  

Expert Review of Neurotherapeutics, Vol. 13, Iss. 6, 2013-06 ,pp. : 707-718

Informa Healthcare

Access to resources Recommend Favorite